Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently amended) A compound of Formula I,



or a pharmaceutically acceptable salt thereof, wherein,

Ar is selected from the following formulae



wherein Ar is substituted with -X and -Y-L-Z, in an ortho relationship to each other, and said Ar is optionally substituted with up to four R¹;

each R^1 is independently selected from -H, halogen, -CN, -NO₂, -OR³, -N(R³)R³, -S(O)₀₋₂R³, -SO₂N(R³)R³, -CO₂R³, -C(O)N(R³)R³, -N(R³)SO₂R³, -N(R³)C(O)R³, -N(R³)CO₂R³, -C(O)R³, -OC(O)R³, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted lower arylalkyl, optionally substituted heterocyclyl, and optionally substituted lower heterocyclylalkyl;

X is selected from the following formulae.

2

wherein R^{4a} is -C(O)N(R³)R³:

n = 1 or 2:

p = 0 or 1;

q is 1 to 3;

M is $-OR^3$ or $-N(R^3)R^4$;

each R^2 is independently selected from -H, haloalkyl, -C_{L-6}alkyl-N(R^3) R^3 , -C_{L-6}alkyl-OR 3 , -C_{L-6}alkyl-CO₂ R^3 , and -C_{L-6}alkyl-C(O)N(R^3) R^3 ;

cach R³ is independently selected from -H, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted lower arylalkyl, optionally substituted heterocyclyl, and optionally substituted lower heterocyclylalkyl; or

two of R³, when taken together with a common nitrogen to which they are attached, form an optionally substituted five- to seven-membered heterocyclyl ring, said optionally substituted five- to seven-membered heterocyclyl ring optionally containing at least one additional heteroatom selected from N, O, S, and P;

each R^4 is independently selected from R^3 , $-SO_2R^3$, $-SO_2N(R^3)R^3$, $-CO_2R^3$, $-C(O)N(R^3)R^3$, and $-C(O)R^3$;

Y-L-Z is selected from the following formulae,

wherein g is zero to two; T is selected from absent, -N(R³)-, -S- and -O-; and each methylene between Y and T is optionally substituted; provided that when both Y and T are heteroatoms then g must be two;

Y is -O- or optionally substituted -CH2-;

 R^5 is selected from -H, halogen, -CN, -NO₂, -OR³, -N(R³)R⁴, -S(O)_{0.2}R³, -SO₂N(R³)R³, -CO₂R³, -CO(O)N(R³)R², -N(R³)SO₂R³, -N(R³)C(O)R³, -N(R³)CO₂R³, -C(O)R³, optionally substituted lower alkyl, optionally substituted aryl,

optionally substituted lower arylalkyl, optionally substituted heterocyclyl, and optionally substituted lower heterocyclylalkyl; and

optionally two of R⁵, together with the atoms to which they are attached, form a second ring system fused with said five- to seven-membered ring system, said second ring system substituted with zero to four of R⁵.

- (Canceled)
- (Canceled)
- 4. (Canceled)
- 5. (Canceled)
- (Canceled)
- (Canceled)
- 8. (Canceled)
- 9. (Canceled)
- (Canceled)
- 11. (Canceled)
- 12. (Previously presented) The compound according to claim 1, wherein g is one or two.
- (Original) The compound according to claim 12, wherein each R⁵ is independently selected from -H, halogen, -CN, -NH₂, -NO₂, -OR³, -N(R³)R⁴, -S(O)₀₋₂R³, -SO₂N(R³)R³, -CO₂R³, -C(O)N(R³)R³, -N(R³)SO₂R³, -N(R³)C(O)R³, -N(R³)CO₂R³, -C(O)R³, and optionally substituted lower alkyl.
- (Currently amended) The compound according to claim 13, wherein -Y-L-Z is selected from the following formulae.





15. (Currently amended) The compound according to claim 4413, having formula III,

Ш

wherein J is N, and B is =N- or $=C(R^5)-$,

R sa is selected from optionally substituted aryl, optionally substituted lower arylalkyl, optionally substituted heterocyclyl, and optionally substituted lower heterocyclylalkyl;

R3b is H. and

R^{4b} is R³, -H, -CO₂R³, -C(O)N(R³)R⁴, or -C(O)R³.

- 16. (Canceled)
- (Currently amended) The compound according to claim +615, wherein R^{3a} is selected from optionally substituted aryl and optionally substituted heteroaryl.
- (Original) The compound according to claim 17, wherein R^{3a} is optionally substituted phenyl.
- 19. (Original) The compound according to claim 18, wherein said optionally substituted phenyl is substituted with at least one of halogen, -CN, -CF₃, -NH₂, -NO₂, -OR³, -N(R³)R³, -S(O)₀₋₂R³, -SO₂N(R³)R³, -CO₂R³, -CO₂R³, -C(O)N(R³)R³, -N(R³)CO₂R³, -N(R³)CO₂R³, -C(O)R³, optionally substituted lower alkyl, and optionally substituted aryl.
- (Original) The compound according to claim 19, wherein said optionally substituted
 phenyl group is substituted with at least one trifluoromethyl group.

- (Original) The compound according to claim 20, wherein said optionally substituted
 phenyl group is substituted with at least two trifluoromethyl groups
- (Original) The compound according to claim 19, wherein said optionally substituted phenyl group is substituted with at least one lower alkyl group.
- 23. (Original) The compound according to claim 19, wherein R3b is -H.
- (Original) The compound according to claim 23, wherein R^{4b} is selected from R³, -H,
 -CO₂R³, -C(O₂N(R³)R⁴, and -C(O₂R³.
- (Canceled)
- (Canceled)
- (Original) The compound according to claim 24, wherein Ar is according to the formula below.

 (Original) The compound according to claim 24, wherein Ar is according to the formula below.

$$\langle \rangle$$

- (Canceled)
- 30. (Previously presented) A compound of Formula IV.

$$(R^{6})_{0.5} = (R^{2})_{0.4} + R$$

IV 6 or a pharmaceutically acceptable salt thereof, wherein,

Ar is selected from the following formulae:



each R^1 is independently selected from -H, halogen, -CN, -NO₂, -OR³, -N(R³)R³, -S(O)₀₋₂R³, -SO₂N(R³)R³, -CO₂R³, -C(O)N(R³)R³, -N(R³)SO₂R³, -N(R³)C(O)R³, -N(R³)CO₂R³, -C(O)R³, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted lower arylalkyl, optionally substituted heterocyclyl, and optionally substituted lower heterocyclylalkyl;

optionally two of R^1 , together with the atoms to which they are attached, form a first ring system fused with Ar, said first ring system substituted with zero to three additional of R^1 :

each R^2 is independently selected from -H, halogen, oxo, -CN, -NH₂, -NO₂, -OR³, -N(R³)R³, -N(R³)R⁵, -S(O) $_{0}$ 2R³, -SO₂N(R³)R³, -CO₂R³, -C(O)N(R³)R³, -N(R³)SO₂R³, -N(R³)C(O)R³, -N(R³)CO₂R³, -N(R³)C(O)N(R³)R³, -C(O)R³, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted lower arylalkyl, optionally substituted heterocyclyl, and optionally substituted lower heterocyclylalkyl;

two of R², together with the atoms to which they are attached, can form an optionally substituted three- to seven-membered ring system;

each R³ is independently selected from -H, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted lower arylalkyl, optionally substituted heterocyclyl, and optionally substituted lower heterocyclylalkyl; or

two of R³, when taken together with a common nitrogen to which they are attached, form an optionally substituted five- to seven-membered heterocyclyl ring, said optionally substituted five- to seven-membered heterocyclyl ring optionally containing at least one additional heteroatom selected from N. O. S. and P:

7

each R^4 is independently selected from R^3 , $-SO_2R^3$, $-SO_2N(R^3)R^3$, $-CO_2R^3$, $-C(O)N(R^3)R^3$, and $-C(O)R^3$;

Y is selected from optionally substituted -CH₂-, -O-, -S-, and -N(R³)-;

L is selected from optionally substituted -CH2-, -O-, -S-, -N(R3) and absent;

provided that Y and L are not both heteroatoms;

B is =N- or =C(H)-:

at each instance, R^5 and R^6 are independently selected from -H, halogen, -CN, -NO₂, -OR³, -N(R³)R⁴, -S(O)₀₋₂R³, -SO₂N(R³)R³, -CO₂R³, -C(O)N(R³)R, -N(R³)SO₂R³, -N(R³)CO₂R³, -C(O)R³, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted lower arylalkyl, optionally substituted heterocyclyl, and optionally substituted lower heterocyclylalkyl; and

optionally two of R⁵, together with the atoms to which they are attached, form a ring system fused with the ring containing B according to formula IV, said ring system substituted with zero to two additional of R⁵.

- (Original) The compound according to claim 30, wherein Y is -O- and L is optionally substituted -CH₂-.
- (Original) The compound according to claim 31, wherein at least one of R⁶ is optionally substituted lower alkyl.
- (Original) The compound according to claim 32, wherein said at least one optionally substituted lower alkyl is meta- to the piperazine urea function as depicted in formula IV.
- (Original) The compound according to claim 33, wherein R^{4a} is selected from R³, -H, -CO₂R³, -C(O)N(R³)R⁴, and -C(O)R³.
- 35. (Original) The compound according to claim 34, wherein R^{4a} is selected from -H, $-CO_2R^3$, $-C(O)N(R^3)R^4$, and $-C(O)R^3$.

8

- 36. (Original) The compound according to claim 35, wherein -Y-L- is -OCH2-.
- (Canceled)

- 38. (Canceled)
- (Original) The compound according to claim 36, wherein Ar is according to the formula below.

 (Original) The compound according to claim 36, wherein Ar is according to the formula below.

$$\langle \rangle$$

- 41. (Canceled)
- 42. (Previously presented) A compound selected from Table 4.

Table 4

97	N-[3,5-bis(trifluoromethyl)phenyl]-4- {3-[(pyridin-4-ylmethyl)oxy]pyridin-2- yl}piperazine-1-earboxamide	HN N N N N N N N N N N N N N N N N N N
103	N-(4-chlorophenyl)-4-{3-[(pyridin-4-ylmethyl)oxy]pyridin-2-yl}piperazine- 1-carboxamide	
105	N-(3-chlorophenyl)-4-{3-[(pyridin-4-ylmethyl)oxy]pyridin-2-yl}piperazine-l-carboxamide	

Table 4

142	4-(3-{[(2-aminopyrimidin-4- yl)methyl]oxy}pyridin-2-yl)-N-[3,5- bis(trifluoromethyl)phenyl]piperazine- 1-carboxamide	HN N N N N N N N N N N N N N N N N N N
144	4-(3-{[(2-aminopyrimidin-4-yl)methyl]oxy}pyridin-2-yl)-N-(3-ethylphenyl)piperazine-1-carboxamide	NH2
161	methyl [4-({[2-(4-{[(3- ethylphenyl)amino]carbonyl}piperazin- 1-yl)pyridin-3-yl]oxy}methyl)pyridin- 2-yl]carbamate	
164	methyl [4-{{[2-(4-{[(3- bromophenyl)amino]carbonyl} piperazi n-1-yl)pyridin-3- yl]oxy} methyl)pyridin-2-yl]carbamate	NH NH NH
165	methyl {4-[({2-[4-({[3- (methyloxy)phenyl]amino}carbonyl)pi perazin-1-yl]pyridin-3- yl}oxy)methyl]pyridin-2-yl}carbamate	NH NN NH

Table 4

166	4-(3-{[(2-aminopyrimidin-4- yl)methyl]oxy] pyridin-2-yl)-N-[3- (methyloxy)phenyl]piperazine-1- carboxamide	NH ₂ N N N N N N N N N N N N N N N N N N N
167	4-(3-{[(2-aminopyrimidin-4- yl)methyl]oxy} pyridin-2-yl)-N-[3-(1- methylethyl)phenyl]piperazine-1- carboxamide	NH ₂ N N NH
168	4-(3-{{(2-aminopyrimidin-4- y))methy [oxy}pyridin-2-yl)-N-{3- [(trifluoromethyl)oxy]phenyl}piperazin e-1-carboxamide	NH2 N N N N N N N N N N N N N N N N N N
169	4-(3-{[(2-aminopyrimidin-4- yl)methyl]oxy]pyridin-2-yl)-N-[2- fluoro-5- (trifluoromethyl)phenyl]piperazine-1- carboxamide	NH ₂
170	N-(3-ethylphenyl)-4-[3-({[2-({[(3-ethylphenyl)amino]carbonyl}amino]pyridin-4-yl]methyl}oxy)pyridin-2-yl]piperazine-1-earboxamide	HN NH NH

Table 4

171	N-(3-ethylphenyl)-4-(3-{[(2-{[(4- methylpiperazin-1- yl)acetyl]amino} pyridin-4- yl)methyl]oxy} pyridin-2-yl)piperazine- 1-carboxamide	NN
173	N-[3,5-bis(trifluoromethyl)phenyl]-4- (3-{[(2-{[(4-methylpiperazin-1- yl)acetyl]amino}pyridin-4- yl)methyl]oxy}pyridin-2-yl)piperazine- l-carboxamide	N N N N N N N N N N N N N N N N N N N
174	4-(3-{[(2-aminopyrimidin-4- yl)methyl]oxy}pyridin-2-yl)-N-[3- (trifluoromethyl)phenyl]piperazine-1- carboxamide	H ₂ N N N N N N N N N N N N N N N N N N N
175	4-[3-({[2-(acetylamino)pyridin-4-yl]methyl}oxy)pyridin-2-yl]-N-(3-ethylphenyl)piperazine-1-carboxamide	NH NH NH
176	4-(3-{[(2-aminopyrimidin-4- yl)methyl]oxy} pyridin-2-yl)-N-(3- ethyl-4-fluorophenyl)piperazine-1- carboxamide	H ₂ N N NH

Table 4

177	2-[4-(3-{[(2-aminopyrimidin-4-yl)methyl]oxy] pyridin-2-yl)piperazin-1-yl]-N-[3,5-bis(trifluoromethyl)phenyl]acetamide	N N N N N N N N N N N N N N N N N N N
178	4-(3-{[(2-aminopyrimidin-4- yl)methyl]oxy}pyridin-2-yl)-N- phenylpiperazine-1-carboxamide	H ₂ N N NH
179	4-(3-{[(2-aminopyrimidin-4- yl)methyl]oxy} pyridin-2-yl)-N-(3- chloro-5-ethylphenyl)piperazine-1- carboxamide	H ₂ N N NH
180	4-(3-{[(2-aminopyrimidin-4- yl)methyl]oxy}pyridin-2-yl)-N-(5- ethyl-2-fluorophenyl)piperazine-1- carboxamide	H ₂ N N N N N N N N N N N N N N N N N N N
181	4-(3-{[(2-aminopyrimidin-4- yl)methyl]oxy}pyridin-2-yl)-N-(3- bromo-5-ethylphenyl)piperazine-1- carboxamide	H ₂ N N N NH

Table 4

182	2-(4-methylpiperazin-1-yl)ethyl [4- ({[2-(4-{[(3- ethylphenyl)amino)earbonyl}piperazin- 1-yl)pyridin-3-yl]oxy}methyl)pyridin- 2-yl]carbamate	
183	4-(3-{[(2-aminopyrimidin-4- yl)methyl]oxy pyridin-2-yl)-N-(3- chlorophenyl)piperazine-1- carboxamide	H ₂ N N N N N N N N N N N N N N N N N N N
184	4-(3-{[(2-aminopyrimidin-4- yl)methyl]oxy j pyridin-2-yl)-N-(3- bromophenyl)piperazine-1- carboxamide	H ₂ N N N NH
185	N-[4-({[2-(4-acetylpiperazin-1- yl)pyridin-3-yl]oxy}methyl)pyridin-2- yl]-2-(4-methylpiperazin-1- yl)acetamide	
186	4-(3-{[(2-aminopyrimidin-4- yl)methyl]oxy]pyridin-2-yl)-N-(3- fluorophenyl)piperazine-1- carboxamide	H ₂ N N N NH

Table 4

_		
187	4-(3-{[(2-aminopyrimidin-4- yl)methyl]oxy] pyridin-2-yl)-N-(4- fluorophenyl)piperazine-1- carboxamide	H ₂ N N NH
188	4-(3-{[(2-aminopyrimidin-4- yl)methyl]oxy]pyridin-2-yl)-N-(2- fluorophenyl)piperazine-1- carboxamide	H ₂ N N N N N N N N N N N N N N N N N N N
189	4-(3-{[(2-aminopyrimidin-4- yl)methyl]oxy}pyridin-2-yl)-N-(3,5- diethylphenyl)piperazine-1- carboxamide	H ₂ N N N NH
190	4-(3-{[(2-aminopyrimidin-4-yl)methyl]oxy}-5-bromopyridin-2-yl)N-(3-ethylphenyl)piperazine-1-carboxamide	Br N N NH
191	N-methyl-4-(3-{[(2-{[(4- methylpiperazin-1- yl)acetyl]amino} pyridin-4- yl)methyl]oxy]pyridin-2-yl)piperazine- 1-carboxamide	N N N N N N N N N N N N N N N N N N N
192	4-(3-{{(2-aminopyrimidin-4- yl)methyl]oxy}pyridin-2-yl)-N-[2- chloro-5- (trifluoromethyl)phenyl]piperazine-1- carboxamide	H ₂ N N N N N N N N N N N N N N N N N N N
193	4-(3-{[(2-aminopyrimidin-4- yl)methyl]oxy] pyridin-2-yl)-N-(5- chloro-2-fluorophenyl)piperazine-1- carboxamide	H ₂ N N CI F

Table 4

194	4-(3-{[(2-amino-5-bromopyrimidin-4-yl)methyl]oxy}-5-bromopyridin-2-yl)-N-(3-ethylphenyl)piperazine-1-carboxamide	Br N N NH
195	4-(3-{[(2-aminopyrimidin-4- yl)methyl]oxy}pyridin-2-yl)-N-[2- fluoro-3- (trifluoromethyl)phenyl]piperazine-1- carboxamide	H ₂ N N N N N N N N N N N N N N N N N N N
196	4-(3-{[(2-aminopyrimidin-4- yl)methyl]oxy} pyridin-2-yl)-N-[3- fluoro-5- (trifluoromethyl)phenyl]piperazine-1- carboxamide	H ₂ N N F CF ₃
197	4-(3-{[(2-aminopyrimidin-4- yl)methyl]oxy} pyridin-2-yl)-N-(3,5- dichlorophenyl)piperazine-1- carboxamide	H ₂ N N CI CI
198	N-(3-chloro-5-ethylphenyl)-4-(3-{[(2- {[(4-methylpiperazin-1- yl)acetyl]amino}pyridin-4- yl)methyl]oxy}pyridin-2-yl)piperazine- 1-carboxamide	N N N N N N N N N N N N N N N N N N N

Table 4

199	N-(5-ethyl-2-fluorophenyl)-4-(3-{[(2- {[(4-methylpiperazin-1- yl)acetyl]amino}pyridin-4- yl)methyl]oxy}pyridin-2-yl)piperazine- 1-carboxamide	N N N N N N N N N N N N N N N N N N N
200	4-(3-{[(2-aminopyrimidin-4- yl)methyl]oxy}pyridin-2-yl)-N-[3- ethyl-5- (trifluoromethyl)phenyl]piperazine-1- carboxamide	H ₂ N N N N N N N N N N N N N N N N N N N
204	4-(3-{[(2-aminopyrimidin-4-yl)methyl]oxy}pyridin-2-yl)-N-methylpiperazine-1-carboxamide	H ₂ N N NH
205	4-(3-{[(2-aminopyrimidin-4-yl)methyl]oxy}pyridin-2-yl)-N-ethylpiperazine-1-carboxamide	H ₂ N N NH
206	4-(3-{[(2-aminopyrimidin-4-yl)methyl]oxy}pyridin-2-yl)-N-cyclohexylpiperazine-1-carboxamide	H ₂ N N N NH
207	4-({[2-(4-acetylpiperazin-1-yl)pyridin-3-yl]oxy}methyl)pyrimidin-2-amine	O N N N N N N N N N N N N N N N N N N N
208	4-({[2-(4-propanoylpiperazin-1-yl)pyridin-3-yl]oxy}methyl)pyrimidin- 2-amine	N N N N N N N N N N N N N N N N N N N

Table 4

209	N-(3-cyclopropylphenyl)-4-(3-{[[2- {[[(4-methylpiperazin-1- yl)acetyl]amino}pyridin-4- yl)methyl]oxy}pyridin-2-yl)piperazine- 1-carboxamide	N N N N N N N N N N N N N N N N N N N
210	4-(3-{[(2-aminopyrimidin-4- yl)methyl]oxy}pyridin-2-yl)-N-(3- cyclopropylphenyl)piperazine-1- carboxamide	H ₂ N N NH
211	N-[2-fluoro-5- (trifluoromethyl)phenyl]-4-(3-{[(2- {[(4-methyl)piperazin-1- yl)acetyl]amino}pyridin-4- yl)methyl]oxy}pyridin-2-yl)piperazine- 1-carboxamide	N N N N N N N N N N N N N N N N N N N
212	N-[3-fluoro-5- (trifluoromethyl)phenyl]-4-(3-{[(2- {[(4-methyl)piperazin-1- yl)acetyl]amino}pyridin-4- yl)methyl]oxy}pyridin-2-yl)piperazine- 1-carboxamide	N N N N N N N N N N N N N N N N N N N
213	N-(3,5-dichlorophenyl)-4-(3-{[(2-{[(4- methylpiperazin-1- yl)acetyl]amino}pyridin-4- yl)methyl]oxy}pyridin-2-yl)piperazine- 1-carboxamide	N N N N N N N N N N N N N N N N N N N

Amendment

Table 4

214	4-(3-{[(2-{[(4-methylpiperazin-1-yl)acetyl]amino}pyridin-4-yl)methyl[oxy]pyridin-2-yl)-N-[3-(trifluoromethyl)piperazine-1-carboxamide	N N N N N N N N N N N N N N N N N N N
216	4-(3-{[1-(2-aminopyrimidin-4- yl)ethyl]oxy pyridin-2-yl)-N-[3,5- bis(trifluoromethyl)phenyl]piperazine- 1-carboxamide	H_2N N F_3C CF_3
219	4-[({2-[4-(3,4-dihydroquinolin-1(2H)- ylcarbonyl)piperazin-1-yl]pyridin-3- yl}oxy)methyl]pyrimidin-2-amine	N N N N N N N N N N N N N N N N N N N
220	4-(3-{[(2-aminopyrimidin-4- yl)methyl]oxy}pyridin-2-yl)-N-(2- methylpropyl)piperazine-1- carboxamide	H ₂ N NH
226	N-(3,5-diethylphenyl)-4-(3-{[(2-{[(4-methylpiperazin-1-yl)acetyl]amino}pyridin-4-yl)oxy]methyl}pyridin-2-yl)piperazine-1-carboxamide	NH NH
227	4-(3-{[(2-aminopyrimidin-4- yl)methyl]oxy}-6-methylpyridin-2-yl)- N-(3-ethylphenyl)piperazine-1- carboxamide	H ₂ N N N N N N N N N N N N N N N N N N N

Table 4

228	4-(3-{[(2-aminopyrimidin-4-yl)methyl]oxy}-6-methylpyridin-2-yl)-N-[3,5-bis(trifluoromethyl)phenyl]piperazine-1-carboxamide	H ₂ N N N N N N N N N N N N N N N N N N N
233	N-[3-chloro-5- (trifluoromethyl)phenyl]-4-(3-{[(2- {[(4-methyl)piperazin-1- yl)acetyl]amino}pyridin-4- yl)methyl]oxy}pyridin-2-yl)piperazine- 1-carboxamide	N N N N N N N N N N N N N N N N N N N
235	4-(3-{[(2-aminopyrimidin-4- yl)methyl]oxy}pyridin-2-yl)-N-[3- chloro-5- (trifluoromethyl)phenyl]piperazine-1- carboxamide	H ₂ N N N NH NH CI
237	4-(3-{[(2-aminopyrimidin-4- yl)methyl]oxy}-6-chloropyridin-2-yl)- N-(3-ethylphenyl)piperazine-1- carboxamide	CI N N NH
243	N-[3-chloro-2-fluoro-5- (trifluoromethyl)phenyl]-4-(3-{[(2- {[(4-methyl)piperazin-1- yl)acetyl]amino}pyridin-4- yl)methyl]oxy}pyridin-2-yl)piperazine- 1-carboxamide	NH P ₃ C F

Table 4

244	4-(3-{[(2-aminopyrimidin-4- yl)methyl]oxy}-6-chloropyridin-2-yl)- N-[3,5- bis(trifluoromethyl)phenyl]piperazine- 1-carboxamide	H_2N N F_3C CF_3
245	4-(3-{[1-(2-aminopyrimidin-4-yl)ethyl]oxy}pyridin-2-yl)-N-(3-ethylphenyl)piperazine-1-carboxamide	H ₂ N N N NH
246	4-(3-{[(2-aminopyrimidin-4- yl)methyl]oxy}-6-chloropyridin-2-yl)- N-(5-ethyl-2-fluorophenyl)piperazine- 1-carboxamide	H ₂ N N N N N N N N N N N N N N N N N N N
247	4-(3-{[(2-aminopyrimidin-4- yl)methyl]oxy}pyridin-2-yl)-N-(3- ethyl-5-fluorophenyl)piperazine-1- earboxamide	H ₂ N N N NH
249	4-(3-{[(2-aminopyrimidin-4- yl)methyl]oxy}pyridin-2-yl)-N-[3- chloro-2-fluoro-5- (trifluoromethyl)phenyl]piperazine-1- carboxamide	H ₂ N N N N N N N N N N N N N N N N N N N
250	4-(3-{[(2-aminopyrimidin-4- yl)methyl]oxy} pyridin-2-yl)-N-[3,5- bis(trifluoromethyl)phenyl]-N- methylpiperazine-1-carboxamide	H ₂ N N N N N N N N N N N N N N N N N N N

 (Previously presented) A pharmaceutical composition comprising the compound according to claim 1 and a pharmaceutically acceptable carrier.

- 44. (Canceled)
- 45. (Canceled)
- 46. (Canceled)
- 47. (Canceled)
- 48. (Canceled)
- 49. (Canceled)
- 50. (Canceled)
- 51. (Canceled)
- 52. (Canceled)
- 53. (Canceled)
- 54. (Canceled)
- 55. (Canceled)
- 56. (Canceled)
- 57. (Canceled)